<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02431585</url>
  </required_header>
  <id_info>
    <org_study_id>GS-IBS</org_study_id>
    <nct_id>NCT02431585</nct_id>
  </id_info>
  <brief_title>Prevalence of Gluten Sensitivity in Irritable Bowel Syndrome: The First Study in Paediatrics.</brief_title>
  <acronym>GS-IBS</acronym>
  <official_title>Prevalence of Gluten Sensitivity in Irritable Bowel Syndrome: The First Study in Paediatrics. (GS-IBS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bari</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Bari</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently a new clinical entity, gluten sensitivity (GS), a form of gluten intolerance in&#xD;
      which neither allergic nor autoimmune mechanisms can be identified, has been added to the&#xD;
      spectrum of gluten-related disorders. This condition is characterized by gastrointestinal and&#xD;
      extra-intestinal symptoms including abdominal pain (68%); eczema or rash (40%); headache&#xD;
      (35%); diarrhoea (33%) and fatigue (33%). The small intestine of GS patient is usually&#xD;
      normal. The prevalence of GS is not yet established although it is estimated that up to 6% of&#xD;
      the general population might be affected. GS has been described only in adults and no data&#xD;
      are available for the paediatric population.The main problem with this new condition is that,&#xD;
      at present, there are no speciﬁc biomarkers to conﬁrm GS diagnosis. In the absence of a&#xD;
      serological or histological marker, the diagnosis remains clinical. In order to avoid placebo&#xD;
      effect of the dietary treatment, presently GS diagnosis needs to performed with double-blind&#xD;
      randomized placebo-controlled challenge provided that both wheat allergy and CD have&#xD;
      previously been excluded.&#xD;
&#xD;
      The primary aim of the study is to evaluate the prevalence of GS in IBS paediatric patients.&#xD;
&#xD;
      The secondary aims are: 1) to describe clinical, serologic, genetic and histological profile&#xD;
      of GS patient and 2) to study the role of gluten or other possible wheat components in the&#xD;
      onset of GS.&#xD;
&#xD;
      Study design Randomized double blind placebo controlled cross over re-challenge trial.&#xD;
      Patient consecutively diagnosed as having IBS (Rome III criteria) in whom the diagnosis of&#xD;
      coeliac disease and wheat allergy has been excluded, will be considered eligible for the&#xD;
      study.&#xD;
&#xD;
      Diagnosis of coeliac disease and wheat allergy will be excluded by the negativity of TTG-IgA&#xD;
      and/or EMA and of Skin Prick Test, RAST immuno-CAP and Atopy patch test respectively.&#xD;
&#xD;
      Patients will entered a three-phase study with a running in phase (phase I: weeks 1-2),&#xD;
      diagnostic elimination diet phase (phase II: week 3-4) and re-challenge phase (phase III:&#xD;
      week 5-12)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized double blind placebo controlled cross over re-challenge trial. Patient&#xD;
      consecutively diagnosed as having IBS (Rome III criteria) in whom the diagnosis of coeliac&#xD;
      disease and wheat allergy has been excluded, will be considered eligible for the study.&#xD;
&#xD;
      Diagnosis of coeliac disease and wheat allergy will be excluded by the negativity of TTG-IgA&#xD;
      and/or EMA and of Skin Prick Test, RAST immuno-CAP and Atopy patch test respectively.&#xD;
&#xD;
      Patients will entered a three-phase study with a running in phase (phase I: weeks 1-2),&#xD;
      diagnostic elimination diet phase (phase II: week 3-4) and re-challenge phase (phase III:&#xD;
      week 5-12).&#xD;
&#xD;
      The following procedure will be performed at different times (Table 1):&#xD;
&#xD;
        1. Entry (Time 0): Blood test, HLA on blood spot, collection of urine and stools;&#xD;
&#xD;
        2. Running-in (phase I: week 1-2): Visual Analogue Scale (VAS) and (IBS-SS); STAIC test;&#xD;
           Bristol stool chart (mBSFC), extra-intestinal symptoms questionnaire.&#xD;
&#xD;
           At the end of week 2 patients still complaining IBS symptoms (IBS-SS&gt;75) will proceed in&#xD;
           the trial and undergo endoscopy plus biopsies on voluntary basis.&#xD;
&#xD;
        3. Diagnostic gluten elimination diet phase (phase II: week 3-4): Visual Analogue Scale&#xD;
           (VAS) and (IBS-SS); STAIC test; Bristol stool chart (mBSF-C), extra-intestinal symptoms&#xD;
           questionnaire. Collection of urine and stools (end of week 4).&#xD;
&#xD;
           At the end of week 4 only patients with a significant reduction of IBS symptoms or VAS&#xD;
           (greater than 30%) will proceed in the re-challenge phase.&#xD;
&#xD;
           The challenge phase will be subdivided in Two phases: one double blind phase (product A&#xD;
           and B) plus a single blind phase (product C).&#xD;
&#xD;
        4. Product A (week 5-6): Visual Analogue Scale (VAS) and (IBS-SS), STAIC test; Bristol&#xD;
           stool chart (mBSF-C), extra-intestinal symptoms questionnaire, collection of urine and&#xD;
           stools (end of week 6);&#xD;
&#xD;
        5. Product B (week 8-9): Visual Analogue Scale (VAS) and (IBS-SS), STAIC test; Bristol&#xD;
           stool chart (mBSF-C), extra-intestinal symptoms questionnaire, collection of urine and&#xD;
           stools (end of week 9)&#xD;
&#xD;
        6. Product C (week 11-12): Visual Analogue Scale (VAS) and (IBS-SS), STAIC test; Bristol&#xD;
           stool chart (mBSF-C), extra-intestinal symptoms questionnaire, collection of urine and&#xD;
           stools (end of week 12)&#xD;
&#xD;
      Challenge procedure&#xD;
&#xD;
      Double Blind phase (Product A and B):&#xD;
&#xD;
      Children will be asked to keep following the strict gluten free diet and to take a sachet&#xD;
      daily for a period of two weeks each interspersed by a washout phase of one week. Sachet will&#xD;
      contain either pure gluten (10 grams daily) or gluten free flour (10 grams daily - SHAR).&#xD;
      Sachets containing placebo will have the same shape, dimension, indication and appearance as&#xD;
      those containing the gluten and will be provided by a bagging factory, which will ensure that&#xD;
      the study will be blinded for investigators and patients. Sachets will be named A or B.&#xD;
&#xD;
      Single Blind Challenge (Product C):&#xD;
&#xD;
      To assess whether other components of wheat other gluten are involved in the onset of GS,&#xD;
      children will be asked to take for a period of two weeks, while on gluten free diet, a muffin&#xD;
      made of wheat flour in a single blind fashion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The standardized questionnaire (IBS-SS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The severity of IBS symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Scale (VAS)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life Questionnaire</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Faces Pain Scale (FPS)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <condition>Gluten Sensitivity</condition>
  <arm_group>
    <arm_group_label>rechallenge</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Double blind placebo controlled cross over</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>gluten</intervention_name>
    <arm_group_label>rechallenge</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>rechallenge</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 4-18 years;&#xD;
&#xD;
          -  IBS diagnosis according to Roma III criteria;&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Coeliac disease;&#xD;
&#xD;
          -  Wheat allergy;&#xD;
&#xD;
          -  Others food allergy;&#xD;
&#xD;
          -  Type 1 Diabetes;&#xD;
&#xD;
          -  Others Chronic and or Malignant diseases;&#xD;
&#xD;
          -  H. Pylori infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ruggiero Francavilla, MD</last_name>
    <phone>00395592063</phone>
    <email>rfrancavilla@me.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pediatric Department &quot;B Trambusti&quot; Ospedale Giovanni XXIII Via Amendola 270</name>
      <address>
        <city>Bari</city>
        <state>Ba</state>
        <zip>70126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernanda Cristofori</last_name>
      <email>fernandacristofori@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ruggiero Francavilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fernanda Cristofori, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Biesiekierski JR, Peters SL, Newnham ED, Rosella O, Muir JG, Gibson PR. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology. 2013 Aug;145(2):320-8.e1-3. doi: 10.1053/j.gastro.2013.04.051. Epub 2013 May 4.</citation>
    <PMID>23648697</PMID>
  </reference>
  <reference>
    <citation>Biesiekierski JR, Newnham ED, Irving PM, Barrett JS, Haines M, Doecke JD, Shepherd SJ, Muir JG, Gibson PR. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol. 2011 Mar;106(3):508-14; quiz 515. doi: 10.1038/ajg.2010.487. Epub 2011 Jan 11.</citation>
    <PMID>21224837</PMID>
  </reference>
  <reference>
    <citation>Volta U, Bardella MT, Calabrò A, Troncone R, Corazza GR; Study Group for Non-Celiac Gluten Sensitivity. An Italian prospective multicenter survey on patients suspected of having non-celiac gluten sensitivity. BMC Med. 2014 May 23;12:85. doi: 10.1186/1741-7015-12-85.</citation>
    <PMID>24885375</PMID>
  </reference>
  <reference>
    <citation>Catassi C, Bai JC, Bonaz B, Bouma G, Calabrò A, Carroccio A, Castillejo G, Ciacci C, Cristofori F, Dolinsek J, Francavilla R, Elli L, Green P, Holtmeier W, Koehler P, Koletzko S, Meinhold C, Sanders D, Schumann M, Schuppan D, Ullrich R, Vécsei A, Volta U, Zevallos V, Sapone A, Fasano A. Non-Celiac Gluten sensitivity: the new frontier of gluten related disorders. Nutrients. 2013 Sep 26;5(10):3839-53. doi: 10.3390/nu5103839. Review.</citation>
    <PMID>24077239</PMID>
  </reference>
  <reference>
    <citation>Carroccio A, Mansueto P, Iacono G, Soresi M, D'Alcamo A, Cavataio F, Brusca I, Florena AM, Ambrosiano G, Seidita A, Pirrone G, Rini GB. Non-celiac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: exploring a new clinical entity. Am J Gastroenterol. 2012 Dec;107(12):1898-906; quiz 1907. doi: 10.1038/ajg.2012.236. Epub 2012 Jul 24.</citation>
    <PMID>22825366</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>October 17, 2014</study_first_submitted>
  <study_first_submitted_qc>April 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2015</study_first_posted>
  <last_update_submitted>April 30, 2015</last_update_submitted>
  <last_update_submitted_qc>April 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Bari</investigator_affiliation>
    <investigator_full_name>Ruggiero Francavilla</investigator_full_name>
    <investigator_title>MD, PHD</investigator_title>
  </responsible_party>
  <keyword>abdominal pain</keyword>
  <keyword>gluten free diet</keyword>
  <keyword>functional gastrointestinal disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

